MENU
+Compare
TAK
Stock ticker: NYSE
AS OF
Feb 21 closing price
Price
$14.06
Change
+$0.20 (+1.44%)
Capitalization
43.11B

TAK Takeda Pharmaceutical Company Limited Forecast, Technical & Fundamental Analysis

a pharmaceutical products manufacturer

TAK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for TAK with price predictions
Feb 21, 2025

TAK's Stochastic Oscillator sits in overbought zone for 3 days

The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TAK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

TAK broke above its upper Bollinger Band on February 21, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on February 14, 2025. You may want to consider a long position or call options on TAK as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for TAK just turned positive on January 27, 2025. Looking at past instances where TAK's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

TAK moved above its 50-day moving average on February 13, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for TAK crossed bullishly above the 50-day moving average on February 06, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TAK advanced for three days, in of 294 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 238 cases where TAK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.963) is normal, around the industry mean (59.993). P/E Ratio (36.794) is within average values for comparable stocks, (90.174). Projected Growth (PEG Ratio) (3.271) is also within normal values, averaging (2.987). Dividend Yield (0.046) settles around the average of (0.122) among similar stocks. P/S Ratio (1.568) is also within normal values, averaging (19.928).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TAK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TAK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

View a ticker or compare two or three
TAK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

TAK is expected to report earnings to fall 398.36% to -14 cents per share on May 08

Takeda Pharmaceutical Company Limited TAK Stock Earnings Reports
Q1'25
Est.
$-0.15
Q4'24
Missed
by $0.05
Q3'24
Beat
by $0.07
Q2'24
Beat
by $0.08
Q1'24
Beat
by $484.00
The last earnings report on January 30 showed earnings per share of 4 cents, missing the estimate of 10 cents. With 1.47M shares outstanding, the current market capitalization sits at 43.11B.
A.I.Advisor
published Dividends

TAK paid dividends on July 08, 2024

Takeda Pharmaceutical Company Limited TAK Stock Dividends
А dividend of $0.29 per share was paid with a record date of July 08, 2024, and an ex-dividend date of March 27, 2024. Read more...
A.I. Advisor
published General Information

General Information

a pharmaceutical products manufacturer

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
1-1, Nihonbashi-Honcho 2-Chome
Phone
+81 332782306
Employees
49095
Web
https://www.takeda.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ASUR11.25-0.16
-1.40%
Asure Software
KFY64.40-1.43
-2.17%
Korn Ferry
WBA10.16-0.35
-3.33%
Walgreens Boots Alliance
DXPE89.91-5.01
-5.28%
DXP Enterprises
ERNA0.31-0.02
-7.08%
Eterna Therapeutics

TAK and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, TAK has been loosely correlated with SGIOY. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if TAK jumps, then SGIOY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TAK
1D Price
Change %
TAK100%
+1.44%
SGIOY - TAK
41%
Loosely correlated
+2.92%
ESAIY - TAK
35%
Loosely correlated
+1.00%
BNXTF - TAK
32%
Poorly correlated
N/A
HLN - TAK
27%
Poorly correlated
+1.82%
TKPHF - TAK
27%
Poorly correlated
N/A
More